Biosynth acquires British firm Pepceuticals

26 September 2023 09:22


Staad/Enderby - The British firm Pepceuticals will become part of Biosynth, a supplier of critical materials for the life sciences industry based in Staad in the canton of St.Gallen. With this acquisition, the company is expanding its range of synthetic peptides produced at large-scale facilities used in the production of these critical materials.

Biosynth, a supplier to the life sciences industry headquartered in the St.GallenBodenseeArea, has acquired the UK firm Pepceuticals, a company that specializes in the production of synthetic peptides based in the vicinity of Leicester. It supplies the life sciences industry with high-quality customer-specific peptides. These complex peptide molecules are produced by the company’s team on the basis of proprietary technology at a purpose-built manufacturing facility. Here, peptides are synthesized in milligram to kilogram quantities.

“The Pepceuticals team has great expertise in optimizing the production of peptides and working at GMP and larger scales”, comments Dr. Urs Spitz, CEO of Biosynth, in the press release. As such, the acquired firm is a “natural fit” for Biosynth’s efforts to expand its peptide offering.

The takeover will strengthen Biosynth’s position in this area, according to comments from Ehab Alramahy, Senior Vice President and Head of Peptide Division: “As we've built the peptide division, our goal has always been to offer a seamless, comprehensive service to our customers. The acquisition represents an important step which allows us to extend our support to clinical trials and commercial supply”. ce/mm

Swiss Pavilion Digital

Previous newsletters